TY - JOUR
T1 - Independent and cumulative association of clinical and morphological heart failure with long-term outcome after percutaneous coronary intervention
AU - Kimura, Mai
AU - Kono, Takashi
AU - Sawano, Mitsuaki
AU - Heidenreich, Paul A.
AU - Ueda, Ikuko
AU - Takahashi, Toshiyuki
AU - Matsubara, Takashi
AU - Ueno, Koji
AU - Hayashida, Kentaro
AU - Yuasa, Shinsuke
AU - Ohki, Takahiro
AU - Fukuda, Keiichi
AU - Kohsaka, Shun
N1 - Funding Information:
Dr Kohsaka received lecture fees and research grants from Pfizer Japan, Bayer, Daiichi Sankyo, and Bristol-Myers Squibb.The present study was funded by the Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (KAKENHI; No. 25460630 and 25460777, 16 KK0186, 16H05215, and 17K09526 https://kaken.nii.ac.jp/ja/index/).
Funding Information:
The present study was funded by the Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (KAKENHI; No. 25460630 and 25460777 , 16 KK0186 , 16H05215 , and 17K09526 https://kaken.nii.ac.jp/ja/index/ ).
Publisher Copyright:
© 2020
PY - 2021/1
Y1 - 2021/1
N2 - Background: Heart failure (HF) is a risk factor for adverse post-procedural outcome after revascularization; however, it is unclear how left ventricular systolic dysfunction (LVSD) and clinical HF symptoms affect percutaneous coronary intervention (PCI) outcomes. We investigated the characteristics and long-term outcomes of patients with clinical HF or LVSD after PCI. Methods: This was a Japanese multicenter registry study of adult patients receiving PCI. Among 4689 consecutive patients who underwent PCI at 15 hospitals from January 2009 to December 2012, we analyzed 2634 (56.2%) with documented left ventricular ejection fraction (LVEF). They were divided into four groups based on clinical HF (symptoms or HF hospitalization) and LVEF [≥35% and <35% (HF due to LVSD)]. The primary outcome was major adverse cardiovascular events (MACE), comprising all-cause death, acute coronary syndrome, HF hospitalization, performance of coronary artery bypass grafting, and stroke within 2 years after the initial PCI. Results: Our findings revealed 354 patients (13.4%) with HF (clinical HF, n = 173, 48.9%; LVSD, n = 132, 37.3%; both, n = 49; 13.8%). The incidence of MACE was higher in patients with clinical HF or LVSD, and was largely due to higher non-cardiac death and HF hospitalization. After adjustment, clinical HF (hazard ratio 2.16, 95% confidence interval; 1.49−3.14) and lower LVEF (per 10%, hazard ratio 0.89, 95% confidence interval; 0.81−0.99) were independently associated with higher MACE risk. Conclusions: Clinical HF and LVSD were independently associated with adverse long-term clinical outcomes, particularly with non-cardiac death and HF readmission, in patients treated with PCI.
AB - Background: Heart failure (HF) is a risk factor for adverse post-procedural outcome after revascularization; however, it is unclear how left ventricular systolic dysfunction (LVSD) and clinical HF symptoms affect percutaneous coronary intervention (PCI) outcomes. We investigated the characteristics and long-term outcomes of patients with clinical HF or LVSD after PCI. Methods: This was a Japanese multicenter registry study of adult patients receiving PCI. Among 4689 consecutive patients who underwent PCI at 15 hospitals from January 2009 to December 2012, we analyzed 2634 (56.2%) with documented left ventricular ejection fraction (LVEF). They were divided into four groups based on clinical HF (symptoms or HF hospitalization) and LVEF [≥35% and <35% (HF due to LVSD)]. The primary outcome was major adverse cardiovascular events (MACE), comprising all-cause death, acute coronary syndrome, HF hospitalization, performance of coronary artery bypass grafting, and stroke within 2 years after the initial PCI. Results: Our findings revealed 354 patients (13.4%) with HF (clinical HF, n = 173, 48.9%; LVSD, n = 132, 37.3%; both, n = 49; 13.8%). The incidence of MACE was higher in patients with clinical HF or LVSD, and was largely due to higher non-cardiac death and HF hospitalization. After adjustment, clinical HF (hazard ratio 2.16, 95% confidence interval; 1.49−3.14) and lower LVEF (per 10%, hazard ratio 0.89, 95% confidence interval; 0.81−0.99) were independently associated with higher MACE risk. Conclusions: Clinical HF and LVSD were independently associated with adverse long-term clinical outcomes, particularly with non-cardiac death and HF readmission, in patients treated with PCI.
KW - Heart failure
KW - Left ventricular systolic dysfunction
KW - Percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=85090124433&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090124433&partnerID=8YFLogxK
U2 - 10.1016/j.jjcc.2020.06.014
DO - 10.1016/j.jjcc.2020.06.014
M3 - Article
C2 - 32888830
AN - SCOPUS:85090124433
SN - 0914-5087
VL - 77
SP - 41
EP - 47
JO - Journal of Cardiography
JF - Journal of Cardiography
IS - 1
ER -